Insider trade

Officer sold ~$174K of MRNA shares in the open market

Traded Jun 4, 2026 · Filed Jun 8, 2026

ModernaMRNA

~$174K
Reported value · 3,471 sh @ $50.00: 67K
Holds after · shares reported: +266.2%
stock since the trade · S&P 500 +0.9%, $51.59 → $188.94 on Oct 1

Why it stands out

Moderna's Chief Legal Officer sold $174K of Moderna shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 4, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 8, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$173,550

Shares × reported transaction price

Timing vs results

34 days after results of May 1, 2026, 57 days before results of Jul 31, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $51.59 on Jun 4, 2026, 131% above its 52-week low and 11% below its high, after a 7% drop over the previous 30 trading days

52-week range $22.36 (Nov 20, 2025) to $57.80 (Mar 4, 2026), 82% of the way up, from 251 adjusted closes. 30 trading days earlier: $55.60 on Apr 22, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant